免疫比浊法试剂市场 - 全球产业规模、份额、趋势、机会、预测：按类型、应用、地区和竞争格局划分，2021-2031年

全球免疫比浊试剂市场预计将从 2025 年的 55.3 亿美元成长到 2031 年的 79.3 亿美元，复合年增长率为 6.19%。

这些试剂是重要的诊断产品，透过测量抗原-抗体反应产生的浊度来定量临床检体中的特定蛋白质浓度。推动这一增长的主要动力是全球慢性疾病负担日益加重，需要频繁监测C反应蛋白和糖化血红蛋白（HbA1c）等生物标记。因此，病理检查室对精确的蛋白质测量工具的需求持续强劲。根据国际糖尿病联盟的数据，到2024年，全球约有5.89亿成年人将患有糖尿病，这项数据凸显了长期诊断监测日益增长的需求。

儘管市场需求强劲，但由于体外诊断领域严格的法规结构，市场仍面临许多障碍。製造商必须应对复杂的合规要求和漫长的新试剂配方核准流程，这往往会导致营运成本增加和市场准入延迟。在实施新的医疗设备法规的地区，这些监管压力尤其突出，对中小企业构成重大挑战。最终，这种环境可能会限制价格敏感型新兴市场中经济实惠的检测解决方案的供应。

市场驱动因素

全球老年人口的成长以及随之而来的合併症增多是免疫比浊试剂市场的主要驱动因素。随着老龄化，全身性发炎和器官功能障碍的风险增加，因此需要定期定量检测特定血浆蛋白，例如免疫球蛋白、微量白蛋白和C反应蛋白。由于老年人通常需要持续管理多种慢性疾病，因此这一人口趋势显着增加了老年医学所需的诊断检测量。世界卫生组织（WHO）于2025年2月发布的数据显示，2024年全球平均寿命将达到73.3岁，凸显了需要医疗监测的时间延长。这一趋势在人口快速老化的地区尤其明显；根据《中国日报》2025年12月报道，到2024年底，中国60岁及以上人口将达到3.1亿，这将形成一个巨大的蛋白质检测市场。

自动化、高通量诊断平台的普及进一步加速了市场成长，这些平台提高了检查室的处理能力和效率。现代病理检查室越来越多地采用模组化系统，利用先进的免疫比浊法快速处理大量检体，最大限度地减少人工干预。这种向自动化的转变需要高度稳定的试剂来确保自动化生产线的准确性，从而确保製造商的持续收入。这种营运模式的变革所带来的财务影响显而易见。罗氏于2025年1月发布的「2024财年业绩」显示，其诊断部门的核心业务收入成长了8%。这主要得益于市场对免疫诊断解决方案的强劲成长动能和需求。

市场挑战

严格的法规结构对全球免疫比浊试剂市场的成长构成重大阻碍。製造商面临着应对复杂合规通讯协定的挑战，包括体外诊断药物法规的修订，这些修订要求进行严格的稳定性检验并提供大量的临床证据。这种严格的监管体系延长了产品核可週期，迫使企业将大量资金投入维持认证而非研发。因此，这些高进入门槛阻碍了中小企业进入市场，迫使现有企业精简产品系列，并常常导致一些在新成本结构下不再具有商业性可行性的小众试剂停产。

监管压力带来的负面影响在企业策略决策中显而易见，这些企业倾向于避免在监管要求最严格的地区推出产品。根据《2024年欧洲医疗技术展报告》，领先的製造商已将欧盟作为新型体外诊断设备主要上市地区的偏好降低了40%，理由是欧盟监管环境资源密集且难以预测。这一趋势将减缓全球先进免疫比浊法的检测法，限制病理检查室及时获得诊断工具，并最终阻碍整体市场收入成长。

市场趋势

随着乳胶增强免疫比浊法的日益普及，市场模式正在重塑。该技术克服了传统检测方法的灵敏度限制。实验室正转向使用这些先进的基于颗粒的配方，无需专用比浊仪，即可使用标准生化分析仪对D-二聚体和Cystatin C等低丰度蛋白进行精确定量。这项技术进步实现了工作流程的整合，并显着降低了每次检测的成本，从而推动了核心病理中心对高性能试剂的需求。近期产业业绩也印证了这项营运优势。 2025年1月，雅培在其「2024财年第四季及全年业绩」报告中指出，不计新冠肺炎相关收入，其全球诊断销售额增长了4.3%，这反映出人们对常规核心检查室检测的依赖性日益增强。

试剂供应的关键发展在于与照护现场和微流体平台的整合，这需要将化学品重新配製成稳定的微量形式，以便进行分散式检查。製造商正积极采用免疫比浊试剂，用于基于卡盒的系统，即使在偏远地区和缺乏湿化学分析仪的急救医疗机构，也能实现快速蛋白质分析。诊断可近性的扩大正在推动全球检测量的成长。根据罗氏于2025年2月发布的2024财年年度报告，2024年全球诊断产业共进行了300亿次检测。这项检测量的成长得益于各项策略性倡议，这些倡议将诊断能力从中心检查室扩展到以病人为中心的医疗机构。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：免疫比浊法试剂的全球市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 类型（普通免疫比浊试剂、乳胶增强型免疫比浊试剂）
  • 透过应用（醣化血红素、视网醇结合蛋白质、C反应蛋白、抗链球菌溶血素O、类风湿因子等）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美免疫比浊法试剂市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲免疫比浊试剂市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区免疫比浊试剂市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲免疫比浊试剂市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲免疫比浊试剂市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球免疫比浊试剂市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Danaher Corporation
• Abbott Laboratories Inc
• Siemens Healthineers AG
• F. Hoffmann-La Roche AG
• DIALAB GmbH
• Shanghai Kehua Bio-Engineering Co Ltd
• Randox Laboratories Ltd
• Beijing Leadman Biochemistry Co Ltd
• Fujifilm Corp
• Mindray Medical International Ltd

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Immunoturbidimetry Reagents Market is projected to expand from a valuation of USD 5.53 Billion in 2025 to USD 7.93 Billion by 2031, reflecting a CAGR of 6.19%. These reagents are essential diagnostic formulations designed to quantify specific protein levels in clinical samples by measuring the turbidity generated from antigen-antibody interactions. A major factor driving this growth is the increasing global burden of chronic diseases, which demands frequent monitoring of biological markers like C-reactive protein and HbA1c. Consequently, pathology laboratories are experiencing a sustained need for accurate protein estimation tools. Data from the International Diabetes Federation indicates that approximately 589 million adults worldwide were living with diabetes in 2024, a statistic that underscores the growing necessity for long-term diagnostic monitoring.

Despite robust demand, the market faces significant hurdles due to the strict regulatory frameworks governing in vitro diagnostics. Manufacturers must navigate intricate compliance mandates and prolonged approval timelines for new reagent formulations, which often result in higher operational costs and delayed market entry. These regulatory pressures are especially intense in regions enforcing new medical device regulations, creating substantial barriers for smaller companies. Ultimately, this environment risks restricting the availability of affordable testing solutions in price-sensitive emerging markets.

Market Driver

The expanding global geriatric population and the rise of associated comorbidities serve as primary catalysts for the immunoturbidimetry reagents market. As individuals age, they become more susceptible to systemic inflammation and organ dysfunction, necessitating regular quantification of specific plasma proteins like immunoglobulins, microalbumin, and C-reactive protein. This demographic trend significantly increases the volume of diagnostic tests required for geriatric care, as older adults frequently need ongoing management for multiple chronic conditions. According to the World Health Organization in February 2025, global life expectancy reached 73.3 years in 2024, emphasizing the extended duration requiring medical monitoring. This is particularly pronounced in rapidly aging regions; China Daily reported in December 2025 that China's population aged 60 and older hit 310 million by the end of 2024, representing a vast market for protein estimation assays.

Market growth is further accelerated by the widespread adoption of automated high-throughput diagnostic platforms, which improve laboratory capacity and efficiency. Modern pathology labs are increasingly adopting modular systems that utilize advanced immunoturbidimetric assays to process large sample volumes rapidly with minimal manual input. This shift towards automation requires high-stability reagents that ensure precision on automated lines, thereby guaranteeing recurring revenue for manufacturers. The financial impact of this operational evolution is clear; Roche's '2024 Annual Results' released in January 2025 noted an 8% increase in the Diagnostics Division's base business sales, driven largely by the strong momentum and demand for immunodiagnostic solutions.

Market Challenge

Strict regulatory frameworks impose a major obstacle to the growth of the Global Immunoturbidimetry Reagents Market. Manufacturers face the challenge of navigating intricate compliance protocols, including updated in vitro diagnostic regulations that necessitate rigorous stability validation and extensive clinical evidence. This intense scrutiny extends the product approval lifecycle and forces companies to direct heavy capital towards maintaining certifications rather than research and development. Consequently, these high entry barriers deter smaller enterprises from competing and compel established companies to streamline their portfolios, frequently resulting in the discontinuation of niche reagents that become commercially unviable under the new cost structures.

The detrimental impact of regulatory pressure is evident in the strategic decision to divert product launches away from regions with the most demanding mandates. According to MedTech Europe in 2024, large manufacturers reduced their prioritization of the European Union as a primary launch geography for new in vitro diagnostic devices by 40%, citing the resource intensity and unpredictability of the regulatory landscape. This trend postpones the global availability of advanced immunoturbidimetry assays, limiting pathology laboratories' access to timely diagnostic tools and ultimately retarding the market's overall revenue growth.

Market Trends

The market is being reshaped by the increasing adoption of latex-enhanced immunoturbidimetry, which resolves the sensitivity limitations of traditional assays. Laboratories are shifting toward these advanced particle-based formulations to accurately quantify low-abundance proteins, such as D-dimer and Cystatin C, on standard biochemistry analyzers without the need for specialized nephelometric equipment. This technological advancement allows for workflow consolidation and a significant reduction in cost-per-test, fueling demand for high-performance reagents in core pathology centers. This operational strength is highlighted by recent industry performance; in January 2025, Abbott reported in its 'Fourth-Quarter and Full-Year 2024 Results' that global Diagnostics sales, excluding COVID-19 revenue, rose by 4.3%, reflecting the growing reliance on routine core laboratory testing.

A critical evolution in reagent delivery is the integration with point-of-care and microfluidic platforms, requiring the reformulation of chemistries into stable, micro-volume formats for decentralized testing. Manufacturers are actively adapting immunoturbidimetric reagents for use in cartridge-based systems, enabling rapid protein profiling in remote settings and urgent care facilities where wet chemistry analyzers are not feasible. This expansion of diagnostic access is driving global testing volumes higher; according to Roche's 'Annual Report 2024' published in February 2025, the Diagnostics division delivered 30 billion tests globally in 2024, a volume supported by the strategic initiative to extend diagnostic capabilities from central labs to near-patient environments.

Key Market Players

• Danaher Corporation
• Abbott Laboratories Inc
• Siemens Healthineers AG
• F. Hoffmann-La Roche AG
• DIALAB GmbH
• Shanghai Kehua Bio-Engineering Co Ltd
• Randox Laboratories Ltd
• Beijing Leadman Biochemistry Co Ltd
• Fujifilm Corp
• Mindray Medical International Ltd

Report Scope

In this report, the Global Immunoturbidimetry Reagents Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Immunoturbidimetry Reagents Market, By Type

• Common Immune Turbidimetric Reagent
• Latex Enhanced Immune Turbidimetric Reagent

Immunoturbidimetry Reagents Market, By Application

• Glycated hemoglobin
• Retinol Binding Protein
• C-Reactive Protein
• Anti-streptococcal hemolysin "O"
• Rheumatoid Factor
• Other

Immunoturbidimetry Reagents Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Immunoturbidimetry Reagents Market.

Available Customizations:

Global Immunoturbidimetry Reagents Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Immunoturbidimetry Reagents Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Common Immune Turbidimetric Reagent, Latex Enhanced Immune Turbidimetric Reagent)
  • 5.2.2. By Application (Glycated hemoglobin, Retinol Binding Protein, C-Reactive Protein, Anti-streptococcal hemolysin "O", Rheumatoid Factor, Other)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Immunoturbidimetry Reagents Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Immunoturbidimetry Reagents Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Immunoturbidimetry Reagents Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Immunoturbidimetry Reagents Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application

7. Europe Immunoturbidimetry Reagents Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Immunoturbidimetry Reagents Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
  • 7.3.2. France Immunoturbidimetry Reagents Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Immunoturbidimetry Reagents Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Immunoturbidimetry Reagents Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Immunoturbidimetry Reagents Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application

8. Asia Pacific Immunoturbidimetry Reagents Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Immunoturbidimetry Reagents Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
  • 8.3.2. India Immunoturbidimetry Reagents Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Immunoturbidimetry Reagents Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Immunoturbidimetry Reagents Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Immunoturbidimetry Reagents Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application

9. Middle East & Africa Immunoturbidimetry Reagents Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Immunoturbidimetry Reagents Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
  • 9.3.2. UAE Immunoturbidimetry Reagents Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
  • 9.3.3. South Africa Immunoturbidimetry Reagents Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application

10. South America Immunoturbidimetry Reagents Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Immunoturbidimetry Reagents Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
  • 10.3.2. Colombia Immunoturbidimetry Reagents Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
  • 10.3.3. Argentina Immunoturbidimetry Reagents Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Immunoturbidimetry Reagents Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Danaher Corporation
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Abbott Laboratories Inc
• 15.3. Siemens Healthineers AG
• 15.4. F. Hoffmann-La Roche AG
• 15.5. DIALAB GmbH
• 15.6. Shanghai Kehua Bio-Engineering Co Ltd
• 15.7. Randox Laboratories Ltd
• 15.8. Beijing Leadman Biochemistry Co Ltd
• 15.9. Fujifilm Corp
• 15.10. Mindray Medical International Ltd

16. Strategic Recommendations

17. About Us & Disclaimer